Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

GSK responds to MSF's plea with pricing explanation--no discount

After urging price concessions for pneumococcal disease vaccines in January and receiving a 20-cent-per-dose discount from Pfizer, Médecins Sans Frontières is sure to be unhappy with GlaxoSmithKline's response.

With GSK swap behind it, Novartis scouts for $2B-$5B buyouts

A little more than a month after completing its big asset swap with GlaxoSmithKline, Novartis CEO Joe Jimenez says he's going back to the bargaining table to look for some bolt-on buyouts in the $2 billion to $5 billion range.

Novartis unleashes M&A scouts as GSK deal starts to deliver on margins

Novartis beat profit estimates for the first quarter, partly because of the big deal closing with GlaxoSmithKline March 2. Now, CEO Joe Jimenez says the Swiss drugmaker is back on the dealmaking trail.

Vietnam-made vaccines WHO-cleared for export

Vietnam has become the 39th nation cleared for global exports of the vaccines it makes, joining an increasingly crowded field of local champions to multinational heavyweights. The World Health Organization gave that clearance recently for a country that expects to be a leading producer within the next 20 to 30 years.

Potency worries prompt GSK flu vaccine recall

To cap off one of the least effective seasons for flu vaccines in recent memory, vaccine producer GlaxoSmithKline announced the recall of all remaining doses of a quadrivalent, affecting roughly 1.7 million jabs.

GSK yanks all doses of quadrivalent flu jab for potency problems

This past season's flu vaccines posted one of the worst efficacy rates in recent memory. That's partly because the viral strains they contained weren't the ones that ended up circulating. But on top of that, GlaxoSmithKline has uncovered some other effectiveness problems of its own--and now it's recalling a quadrivalent jab in a move that affects 1.7 million doses.

GSK closing Pittsburgh office, putting 275 jobs at risk

The big asset swap between GlaxoSmithKline and Novartis may have given each just what it wanted, but the deal continues to play out poorly for workers, with GSK planning to close its Pittsburgh office where it has about 275 employees working for its consumer health unit.

Careful, European drugmakers. Fitch says M&A may be a bit too heated

Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.

With U.S. sales suffering, GSK plots changes to quota-free pay model

GlaxoSmithKline's controversial overhaul of sales-rep compensation is due for some tweaks. After replacing its North American president earlier this year, the company has decided to revisit its so-called Patient First sales model, which pegs incentive pay to broad sales and performance goals rather than individual quotas.

GSK relocates vaccine R&D to Maryland with new global center

In the wake of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline is doubling down on its vaccines focus. And it'll be doing that in Maryland, where it's establishing a new global R&D center.